Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.
Novavax Inc. (Nasdaq: NVAX) is a clinical-stage biotechnology company dedicated to developing vaccines to prevent infectious diseases. Based in Gaithersburg, Maryland, with facilities in Rockville, Maryland, and Uppsala, Sweden, Novavax employs over 300 professionals focused on innovation in vaccine development.
Novavax leverages its proprietary recombinant nanoparticle technology and Matrix-M™ adjuvant to create vaccines that stimulate strong immune responses. The company's product pipeline includes vaccine candidates for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza, and Ebola virus. Additionally, their pipeline includes preclinical programs targeting various infectious diseases.
Recently, Novavax has made significant strides in COVID-19 vaccine development. The company announced that its Nuvaxovid™ XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) received Emergency Use Listing (EUL) from the World Health Organization (WHO). This listing expedites the regulatory approval process, enabling broader global distribution. The vaccine is also authorized in the U.S. and the European Union and is under review in other markets.
Novavax's updated COVID-19 vaccine can be stored at temperatures between 2 to 8 degrees Celsius and has a 12-month shelf life, simplifying logistics and reducing waste. This vaccine has shown efficacy against multiple variants, including BA.2.86, EG.5.1, and XBB.1.16.6.
In addition to their COVID-19 efforts, Novavax has entered a co-exclusive licensing agreement with Sanofi to enhance the distribution of their standalone adjuvanted COVID-19 vaccine and develop combination vaccines. This partnership highlights the company's commitment to leveraging its technology to address global health challenges.
Financially, Novavax has shown a strong performance with updated financial guidance for 2024. With over $1 billion in potential contract value for advance purchase agreements, Novavax is well-positioned to deliver on its commitments while focusing on expanding its product portfolio.
Overall, Novavax Inc. represents a significant player in the biotechnology sector, continuously pushing the boundaries of vaccine development to address pressing global health issues.
Novavax, Inc. (Nasdaq: NVAX) reported fourth-quarter 2022 revenues of $357 million, a 61% increase year-over-year, and full-year revenues of $2.0 billion, reflecting 73% growth. The company updated its agreement with the U.S. government for an additional 1.5 million COVID-19 vaccine doses in 2023. Significant developments include the expansion of the Nuvaxovid™ label and initiation of a Phase 2 trial for a COVID-19-Influenza Combination vaccine. Despite a net loss of $182 million in Q4, down from $846 million in Q4 2021, cash reserves stand at $1.3 billion as of year-end 2022. Novavax aims to enhance efficiency and drive long-term value amid ongoing uncertainties.
Novavax, Inc. (NASDAQ: NVAX) will release its fourth quarter and full-year 2022 financial results on February 28, 2023, at 4:30 p.m. EST. The call will discuss operational highlights and include a Q&A session. Participants are encouraged to join early and can access the call through a webcast. A replay will be available from 7:30 p.m. EST on the same day until March 7, 2023. Novavax focuses on developing innovative vaccines for serious infectious diseases, enhancing vaccine efficacy through its patented Matrix-M adjuvant technology.
Novavax, Inc. (Nasdaq: NVAX) announced the extension of its agreement with the U.S. Department of Health and Human Services, securing up to 1.5 million doses of its COVID-19 vaccine, NVX-CoV2373. The modified agreement aims to enhance public access to the vaccine and includes plans for smaller dose vials and strain selection aligned with FDA guidance. The partnership highlights the importance of Novavax's protein-based vaccine in the U.S. COVID-19 vaccination campaign for 2023/2024. The vaccine is authorized for emergency use, primarily for individuals aged 12 and over, and will be provided free to states and healthcare partners.
On January 25, 2023, Novavax (NASDAQ: NVAX) announced the grant of inducement awards to its new President and CEO, John C. Jacobs, effective January 23, 2023. The awards include a non-qualified stock option for 290,700 shares at an exercise price of $11.92, with a ten-year term and a vesting schedule based on continued employment. Additionally, 249,590 restricted stock units will vest over three years. This action is in compliance with Nasdaq Listing Rule 5635(c)(4) and the 2023 Inducement Plan, reflecting the company's commitment to attracting top talent as it continues to develop next-generation vaccines.
Novavax, Inc. (NVAX) announced that its partner SK bioscience has received expanded approval from the Korean Ministry of Food and Drug Safety for Nuvaxovid (NVX-CoV2373) to be used as a booster for COVID-19 in adults aged 18 and older. This decision follows prior recommendations from the Korean Centers for Disease Control and Prevention. The approval is based on data from Novavax's Phase 2 trials, which showed increased immune responses following the booster. Nuvaxovid is now authorized for use as a booster in over 35 countries. The vaccine utilizes Novavax's proprietary technology and is under review in additional markets for further indications.
Novavax, Inc. (Nasdaq: NVAX) announced that John C. Jacobs will succeed Stanley C. Erck as President and CEO effective January 23, 2023. Erck will assist in the leadership transition for 15 months. Jacobs brings over 25 years of industry experience, having led Harmony Biosciences through its IPO and FDA product approval. Under Erck's leadership since 2011, Novavax launched its COVID-19 vaccine in over 40 countries. The company is positioned to continue its strategic development with multiple vaccine candidates in progress.
Novavax, Inc. (Nasdaq: NVAX) has initiated a Phase 2 trial for its COVID-19-Influenza Combination (CIC) vaccine and a stand-alone influenza vaccine. This dose-confirming trial will assess safety and immunogenicity in adults aged 50-80 and aims to enroll around 2,300 participants across Australia and New Zealand. Initial results are expected mid-2023, which will guide the Phase 3 trials. The company draws optimism from earlier positive results from the Phase 1/2 trial, focusing on providing better protection against influenza and COVID-19, especially for older adults.
On December 20, 2022, Novavax (Nasdaq: NVAX) completed a $150 million offering of 5.00% Senior Convertible Notes due 2027, with an additional $25.25 million purchased by initial buyers. Also, a public offering of 7,475,000 shares of common stock raised $74.75 million. The combined gross proceeds from both offerings amount to $250 million. The Notes are convertible at $12.50 per share, representing a 25% conversion premium. Novavax estimates net proceeds of approximately $166.3 million from the Notes and $69.8 million from the stock offering, earmarked for corporate purposes.
Novavax, Inc. (Nasdaq: NVAX) announced a $150 million offering of 5.00% convertible senior notes due 2027, with an option for initial purchasers to buy an additional $25.25 million. The notes will accrue interest semi-annually and are redeemable post December 22, 2025. Concurrently, a public offering of 6,500,000 shares of common stock at $10.00 per share, totaling $65 million, has been priced. Proceeds will support global launches, operational costs, and R&D. Offerings are expected to close on December 20, 2022.
Novavax, Inc. (Nasdaq: NVAX) has announced the pricing of a public offering of 6,500,000 shares of common stock at $10.00 per share, raising approximately $65 million. The underwriters have a 30-day option to buy an additional 975,000 shares. Concurrently, Novavax priced $150 million in convertible senior notes due in 2027. The net proceeds will be used for general corporate purposes, including the global launch of Nuvaxovid and repaying outstanding senior notes. Both offerings are expected to close on December 20, 2022, subject to customary conditions.
FAQ
What is the current stock price of Novavax (NVAX)?
What is the market cap of Novavax (NVAX)?
What is Novavax Inc. known for?
Where is Novavax Inc. headquartered?
What recent achievements has Novavax made?
What is the storage requirement for Novavax's COVID-19 vaccine?
Who are Novavax’s main partners?
What are the key products in Novavax's pipeline?
How does Novavax’s Matrix-M™ adjuvant work?
What financial performance is expected from Novavax in 2024?
Is Novavax's COVID-19 vaccine effective against variants?
What is the significance of Novavax's partnership with Sanofi?
